Novo Nordisk in short
Novo Nordisk sales totalled DKK 45.553 million (EUR 6.109 million) in 2008. With headquarters in Denmark, Novo Nordisk employs approximately 26.500 full-time employees in 81 countries, and markets its products in 179 countries.
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society.
Triple bottom line focus
Novo Nordisk is committed to developing its business towards ecological, social and economic sustainability. This commitment is demonstrated through its values and its environmental and social responsibility policies.
Stock exchange listings
Novo Nordisk’s B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’.
Our Vision paints a picture of what Novo Nordisk wants to achieve as a company - our place in the market and our overall goals in relation to patients, society and employees.
How we act is described in the Charter. The Charter describes our Values, Commitments and Fundamentals - our basic management principles. Novo Nordisk has adopted the Charter for companies in the Novo Group - we commit ourselves to act inside this framework.
